moneyheap
XENE · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Xenon Pharmaceuticals Inc (XENE) stock moving?
Xenon reported Q3 2026 results on Nov 9 with a loss of $1.11 per share, slightly better than the $1.13 estimate, and said the azetukalner NDA for focal seizures was submitted to the FDA in September. Management pointed to $1.2 billion in cash with runway into 2029, the Phase 3 X-NOVA2 MDD topline readout now expected in December 2026, and a planned Q1 2027 start for the X-FIRST add-on study. Positive Phase 1 data for the non-opioid pain candidates XEN1701 and XEN1120 on Oct 29 added to the pipeline story. The stock closed at 41.39 on Nov 10, the highest close in the 30-day window, up about 13% from 36.50 on Oct 22 and 2.3% on the day after results. Volume on Nov 10 was about 2.09M shares, roughly 1.5 times the 14-day average near 1.39M, which suggests the earnings reaction has real participation. The recent range is 35.09 to 41.48. Two 13G ownership filings from FMR and T. Rowe Price are passive disclosures and add little directional signal. The EPS beat was small, and the main binary catalyst, the December MDD readout, still lies ahead, so the near-term move may be vulnerable to a pullback if sentiment cools.
News behind the analysis
- Xenon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business UpdateXenon reported Q3 2026 results and said an NDA for azetukalner in focal seizures was submitted to the FDA in September 2026. Cash, equivalents and marketable securities were $1.2 billion, with runway into 2029.
- Xenon Pharmaceuticals Q3 EPS $(1.11) Beats $(1.13) EstimateXenon's third-quarter loss per share of $1.11 was slightly narrower than the $1.13 consensus estimate.
- Xenon Pharmaceuticals Q3 2026 Earnings Call TranscriptManagement reiterated confidence in azetukalner's epilepsy profile and said the X-NOVA2 Phase 3 MDD topline readout is now expected in December 2026.
- T. Rowe Price Investment Management Files Schedule 13G for Xenon PharmaceuticalsT. Rowe Price Investment Management reported an ownership stake in Xenon in a Schedule 13G filed on November 6, 2026.
- FMR LLC Files Schedule 13G Regarding Xenon PharmaceuticalsFMR LLC filed a Schedule 13G indicating a change in its ownership stake in Xenon.
- Xenon Pharmaceuticals Announces Participation in Upcoming Investor ConferencesXenon will present at four investor conferences during the fourth quarter of 2026.
- Xenon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026Xenon scheduled its Q3 2026 results and business update for after the market close on November 9, 2026.
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xenon granted 24,250 share options and 14,250 restricted share units to nine new non-officer employees.
- Xenon Pharmaceuticals Announces Positive Phase 1 Results and Preclinical Data for Acute Pain Candidates XEN1701 and XEN1120Positive Phase 1 results and new preclinical data for XEN1701 and XEN1120 support advancing both acute pain candidates into Phase 2 proof-of-concept studies.
- Xenon Pharmaceuticals Announces Its XEN1701 Surpasses Target Profile; Data Presented During International Association For The Study Of Pain 2026 World Congress On PainBenzinga reported that XEN1701 surpassed its target profile in data presented at the IASP 2026 World Congress on Pain.
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals is a late-stage biotech company based in Vancouver and Boston that develops drugs for neurological and psychiatric conditions, with a focus on ion channels (proteins that control electrical signals in nerve cells). Its lead drug candidate is azetukalner, a once-daily Kv7 potassium channel opener taken without dose ramp-up. It had positive Phase 3 results in focal onset seizures in March 2026, and the company planned to file for FDA approval in Q3 2026.
How it makes money
Xenon has no approved products yet, so it earns little or no product revenue. It mainly pays for its work with cash from selling shares, including a raise of roughly $750 million in March 2026, and says it has enough cash to last into 2029. Any future income would mainly come from sales of azetukalner if it is approved, with possible occasional partnership or licensing payments.
What usually moves XENE
- FDA review and approval decision for azetukalner in epilepsy
- Phase 3 depression results (X-NOVA2 topline expected H1 2027) and bipolar depression trial progress
- Commercial launch readiness and how well the drug sells if approved
- Early pipeline updates, such as Nav1.7 pain programs
- Biotech sector sentiment and future share sales that could dilute existing holders